Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

BRM270

 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Jiedu Xiaozheng Yin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
BRM270 Suppresses Cervical Cancer Stem Cell Characteristics and Progression by Inhibiting SOX2
Background/Aim: Cervical cancer is one of the leading causes of cancer death in women worldwide. BRM270 (BRMLife) has therapeutic… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2019
2019
BRM270 Inhibits the Proliferation of CD44 Positive Pancreatic Ductal Adenocarcinoma Cells via Downregulation of Sonic Hedgehog Signaling
Pancreatic cancer has a poor survival rate as compared to other types of cancer. Surface marker CD44 plays important role in… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
2019
2019
Synthesis and evaluation of the antiproliferative efficacy of BRM270 phytocomposite nanoparticles against human hepatoma cancer cell lines.
  • M. Gera, N. Kim, +9 authors D. Jeong
  • Materials science & engineering. C, Materials for…
  • 2019
    • Corpus ID: 59251429
BRM270 is the most leading phytochemical extract that possesses potent anticancer properties. A major challenge associated with… Expand
2018
2018
BRM270 inhibits cancer stem cell maintenance via microRNA regulation in chemoresistant A549 lung adenocarcinoma cells
Chemotherapy is a standard treatment for non-small-cell lung cancer (NSCLC). However, the dose-limiting toxicity of drugs and the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2017
2017
BRM270, a Compound from Natural Plant Extracts, Inhibits Glioblastoma Stem Cell Properties and Glioblastoma Recurrence.
Glioblastoma multiforme (GBM) is one of the most aggressive and lethal human brain tumors, and the median survival of patients… Expand
2017
2017
Novel phyto-derivative BRM270 inhibits hepatocellular carcinoma cells proliferation by inducing G2/M phase cell cycle arrest and apoptosis in xenograft mice model.
Hepatocellular carcinoma (HCC) is a major threat to human health worldwide and development of novel antineoplastic drug is… Expand
2016
2016
Epigenetic induction of epithelial to mesenchymal transition by LCN2 mediates metastasis and tumorigenesis, which is abrogated by NF-κB inhibitor BRM270 in a xenograft model of lung adenocarcinoma
Tumor initiating cancer stem-like cells (TICSCs) have recently become the object of intensive study. Human-Lipocalin-2 (hLCN2… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2015
2015
The novel inhibitor BRM270 downregulates tumorigenesis by suppression of NF-κB signaling cascade in MDR-induced stem like cancer-initiating cells.
The nuclear factor κB (NF-κB) and interleukin-6 (IL-6) contribute to multidrug resistance (MDR) in tumor chemotherapy. The… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE